Astellas Pharma Stock Net Asset
ALPMF Stock | USD 9.52 0.32 3.25% |
Astellas Pharma fundamentals help investors to digest information that contributes to Astellas Pharma's financial success or failures. It also enables traders to predict the movement of Astellas Pink Sheet. The fundamental analysis module provides a way to measure Astellas Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Astellas Pharma pink sheet.
Astellas |
Astellas Pharma Company Net Asset Analysis
Astellas Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Astellas Pharma Net Asset | 2.33 T |
Most of Astellas Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Astellas Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
Based on the recorded statements, Astellas Pharma has a Net Asset of 2.33 T. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net asset for all United States stocks is notably lower than that of the firm.
Astellas Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astellas Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics of similar companies.Astellas Pharma is currently under evaluation in net asset category among related companies.
Astellas Fundamentals
Return On Equity | 0.0898 | |||
Return On Asset | 0.0653 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.17 % | |||
Current Valuation | 26.19 B | |||
Shares Outstanding | 1.83 B | |||
Shares Owned By Insiders | 0.37 % | |||
Shares Owned By Institutions | 50.43 % | |||
Price To Earning | 25.09 X | |||
Price To Book | 2.38 X | |||
Price To Sales | 0.02 X | |||
Revenue | 1.3 T | |||
Gross Profit | 1.04 T | |||
EBITDA | 241.52 B | |||
Net Income | 124.09 B | |||
Cash And Equivalents | 336.76 B | |||
Cash Per Share | 184.77 X | |||
Total Debt | 4.87 B | |||
Debt To Equity | 0 % | |||
Current Ratio | 1.34 X | |||
Book Value Per Share | 861.58 X | |||
Cash Flow From Operations | 257.44 B | |||
Earnings Per Share | 0.57 X | |||
Target Price | 50.0 | |||
Number Of Employees | 14.52 K | |||
Beta | 0.51 | |||
Market Capitalization | 26.66 B | |||
Total Asset | 2.33 T | |||
Retained Earnings | 941.23 B | |||
Working Capital | 491.17 B | |||
Current Asset | 874.69 B | |||
Current Liabilities | 383.53 B | |||
Z Score | 3.0 | |||
Annual Yield | 0.03 % | |||
Five Year Return | 2.25 % | |||
Net Asset | 2.33 T | |||
Last Dividend Paid | 25.0 |
About Astellas Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Astellas Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Astellas Pharma's short interest history, or implied volatility extrapolated from Astellas Pharma options trading.
Pair Trading with Astellas Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astellas Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astellas Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Astellas Pink Sheet
0.8 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
0.63 | RHHBY | Roche Holding | PairCorr |
Moving against Astellas Pink Sheet
0.65 | AZN | AstraZeneca PLC ADR | PairCorr |
0.6 | AZNCF | AstraZeneca PLC | PairCorr |
The ability to find closely correlated positions to Astellas Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astellas Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astellas Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astellas Pharma to buy it.
The correlation of Astellas Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astellas Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astellas Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astellas Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Astellas Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Astellas Pink Sheet analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |